| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1:2000-1:5000 | Human,Mouse,Rat |
| Aliases | chemokine (C-C motif) ligand 3-like 1, LD78, 464.2, MIP1AP, SCYA3L, G0S19-2, SCYA3L1, D17S1718, LD78BETA |
| WB Predicted band size | 10kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthetic peptide corresponding to a region derived from 80-93 amino acids of human chemokine (C-C motif) ligand 3-like 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CCL3L1抗体的参考文献示例(注：内容为虚构示例，实际文献需通过学术数据库验证)：
1. **文献名称**：CCL3L1-specific antibodies inhibit HIV-1 entry in vitro
**作者**：Dolan MJ, et al.
**摘要**：研究报道了针对CCL3L1的抗体通过阻断其与CCR5受体的结合，抑制HIV-1病毒进入靶细胞，提示其在抗病毒治疗中的潜在应用。
2. **文献名称**：Genetic variation of CCL3L1 copy number modulates antibody response in autoimmune diseases
**作者**：Gonzalez E, et al.
**摘要**：探讨CCL3L1基因拷贝数多态性与自身免疫病患者血清中抗CCL3L1抗体水平的关系，发现低拷贝数个体抗体反应增强，可能与疾病进展相关。
3. **文献名称**：Development of a monoclonal antibody for detecting CCL3L1 in tumor microenvironments
**作者**：Smith A, et al.
**摘要**：开发了一种高特异性单克隆抗体，用于检测癌症组织中CCL3L1的表达，并验证其与肿瘤炎症浸润及预后的关联。
4. **文献名称**：Structural characterization of CCL3L1-antibody complexes reveals novel binding epitopes
**作者**：Johnson R, et al.
**摘要**：通过X射线晶体学解析CCL3L1蛋白与抗体的复合物结构，揭示了关键结合表位，为基于抗体的药物设计提供理论依据。
建议通过PubMed、Google Scholar等平台检索真实文献，使用关键词“CCL3L1 antibody”、“CCL3L1 therapeutic”或结合具体研究领域(如HIV、癌症)进行筛选。
The CCL3L1 antibody is designed to target the C-C motif chemokine ligand 3-like 1 (CCL3L1), a protein encoded by a gene located on chromosome 17q12. CCL3L1 belongs to the CC chemokine family and shares structural homology with CCL3 (also known as MIP-1α). It functions as a potent chemoattractant for immune cells, including monocytes, macrophages, and T-cells, by binding to chemokine receptors such as CCR1. CCR3. and CCR5. Notably, CCL3L1 competes with CCL3 for receptor binding, modulating inflammatory responses and immune regulation.
CCL3L1 has gained attention due to its copy number variation (CNV) across populations, influencing individual susceptibility to infectious and autoimmune diseases. For example, lower CCL3L1 copy numbers are associated with increased HIV/AIDS progression risk, likely due to reduced CCR5 receptor blockade. Conversely, elevated copies may correlate with autoimmune conditions like rheumatoid arthritis.
Antibodies against CCL3L1 are primarily used in research to quantify protein expression, study its interaction with receptors, and explore its role in disease mechanisms. These antibodies are validated for applications such as Western blotting, immunohistochemistry, and flow cytometry. Understanding CCL3L1's function through antibody-based assays contributes to insights into immune dysregulation, therapeutic target identification, and biomarker development for diseases linked to chemokine signaling pathways.
×
